|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goldberg RM, Rothenberg ML, Van Cutsem E,
Benson AB III, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol
NJ, Ramanathan RK, et al: The continuum of care: A paradigm for the
management of metastatic colorectal cancer. Oncologist. 12:38–50.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang J and Manley JL: Misregulation of
pre-mRNA alternative splicing in cancer. Cancer Discov.
3:1228–1237. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ladomery M: Aberrant alternative splicing
is another hallmark of cancer. Int J Cell Biol. 2013:4637862013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou X, Li X, Cheng Y, Wu W, Xie Z, Xi Q,
Han J, Wu G, Fang J and Feng Y: BCLAF1 and its splicing regulator
SRSF10 regulate the tumorigenic potential of colon cancer cells.
Nat Commun. 5:45812014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reyes-Turcu FE, Ventii KH and Wilkinson
KD: Regulation and cellular roles of ubiquitin-specific
deubiquitinating enzymes. Annu Rev Biochem. 78:363–397. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Leuken RJ, Luna-Vargas MP, Sixma TK,
Wolthuis RM and Medema RH: Usp39 is essential for mitotic spindle
checkpoint integrity and controls mRNA-levels of aurora B. Cell
Cycle. 7:2710–2719. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ríos Y, Melmed S, Lin S and Liu NA:
Zebrafish usp39 mutation leads to rb1 mRNA splicing defect and
pituitary lineage expansion. PLoS Genet. 7:e10012712011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang H, Ji X, Liu X, Yao R, Chi J, Liu S,
Wang Y, Cao W and Zhou Q: Lentivirus-mediated inhibition of USP39
suppresses the growth of breast cancer cells in vitro. Oncol
Rep. 30:2871–2877. 2013.PubMed/NCBI
|
|
10
|
Huang Y, Pan XW, Li L, Chen L, Liu X, Lu
JL, Zhu XM, Huang H, Yang QW, Ye JQ, et al: Overexpression of USP39
predicts poor prognosis and promotes tumorigenesis of prostate
cancer via promoting EGFR mRNA maturation and transcription
elongation. Oncotarget. 7:22016–22030. 2016.PubMed/NCBI
|
|
11
|
Yuan X, Sun X, Shi X, Jiang C, Yu D, Zhang
W, Guan W, Zhou J, Wu Y, Qiu Y, et al: USP39 promotes the growth of
human hepatocellular carcinoma in vitro and in vivo.
Oncol Rep. 34:823–832. 2015.PubMed/NCBI
|
|
12
|
Lou YF, Zou ZZ, Chen PJ, Huang GB, Li B,
Zheng DQ, Yu XR and Luo XY: Combination of gefitinib and DNA
methylation inhibitor decitabine exerts synergistic anti-cancer
activity in colon cancer cells. PLoS One. 9:e977192014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang J, Tsoi H, Li X, Wang H, Gao J, Wang
K, Go MY, Ng SC, Chan FK, Sung JJ, et al: Carbonic anhydrase IV
inhibits colon cancer development by inhibiting the Wnt signalling
pathway through targeting the WTAP-WT1-TBL1 axis. Gut. 13:e78–e79.
2015.
|
|
14
|
Park J and Jeong S: Wnt activated
β-catenin and YAP proteins enhance the expression of non-coding RNA
component of RNase MRP in colon cancer cells. Oncotarget.
6:34658–34668. 2015.PubMed/NCBI
|
|
15
|
Jung O, Lee J, Lee YJ, Yun JM, Son YJ, Cho
JY, Ryou C and Lee SY: Timosaponin AIII inhibits migration and
invasion of A549 human non-small-cell lung cancer cells via
attenuations of MMP-2 and MMP-9 by inhibitions of ERK1/2, Src/FAK
and β-catenin signaling pathways. Bioorg Med Chem Lett.
26:3963–3967. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shalaby MA, Nounou HA, Ms AOA, Azzam N and
Saeed HM: Associations between single nucleotide polymorphisms of
COX-2 and MMP-2 genes and colorectal cancer susceptibility in the
Saudi population. Asian Pac J Cancer Prev. 15:4989–4994. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ao N and Liu Y, Bian X, Feng H and Liu Y:
Ubiquitin-specific peptidase 22 inhibits colon cancer cell invasion
by suppressing the signal transducer and activator of transcription
3/matrix metalloproteinase 9 pathway. Mol Med Rep. 12:2107–2113.
2015.PubMed/NCBI
|
|
18
|
Moon RT, Brown JD and Torres M: WNTs
modulate cell fate and behavior during vertebrate development.
Trends Genet. 13:157–162. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu M, Wang S, Song YU, Yao J, Huang K and
Zhu X: Apigenin suppresses colorectal cancer cell proliferation,
migration and invasion via inhibition of the Wnt/β-catenin
signaling pathway. Oncol Lett. 11:3075–3080. 2016.PubMed/NCBI
|
|
20
|
Li X, Zhang X, Liu X, Tan Z, Yang C, Ding
X, Hu X, Zhou J, Xiang S, Zhou C, et al: Caudatin induces cell
apoptosis in gastric cancer cells through modulation of
Wnt/β-catenin signaling. Oncol Rep. 30:677–684. 2013.PubMed/NCBI
|
|
21
|
Fu Y, Zheng S, An N, Athanasopoulos T,
Popplewell L, Liang A, Li K, Hu C and Zhu Y: β-catenin as a
potential key target for tumor suppression. Int J Cancer.
129:1541–1551. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim W, Kim M and Jho EH: Wnt/β-catenin
signalling: From plasma membrane to nucleus. Biochem J. 450:9–21.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tutton MG, George ML, Eccles SA, Burton S,
Swift RI and Abulafi AM: Use of plasma MMP-2 and MMP-9 levels as a
surrogate for tumour expression in colorectal cancer patients. Int
J Cancer. 107:541–550. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee MA, Park JH, Rhyu SY, Oh ST, Kang WK
and Kim HN: Wnt3a expression is associated with MMP-9 expression in
primary tumor and metastatic site in recurrent or stage IV
colorectal cancer. BMC Cancer. 14:125–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu B, Crampton SP and Hughes CC: Wnt
signaling induces matrix metalloproteinase expression and regulates
T cell transmigration. Immunity. 26:227–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zuo F, Kaminski N, Eugui E, Allard J,
Yakhini Z, Ben-Dor A, Lollini L, Morris D, Kim Y, DeLustro B, et
al: Gene expression analysis reveals matrilysin as a key regulator
of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA.
99:6292–6297. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Orlichenko LS and Radisky DC: Matrix
metalloproteinases stimulate epithelial-mesenchymal transition
during tumor development. Clin Exp Metastasis. 25:593–600. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fagan-Solis KD, Schneider SS, Pentecost
BT, Bentley BA, Otis CN, Gierthy JF and Arcaro KF: The RhoA pathway
mediates MMP-2 and MMP-9-independent invasive behavior in a
triple-negative breast cancer cell line. J Cell Biochem.
114:1385–1394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gill S, Blackstock AW and Goldberg RM:
Colorectal cancer. Mayo Clin Proc. 82:114–129. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cheng YD, Yang H, Chen GQ and Zhang ZC:
Molecularly targeted drugs for metastatic colorectal cancer. Drug
Des Devel Ther. 7:1315–1322. 2013.PubMed/NCBI
|
|
31
|
Peng X, Luo Z, Kang Q, Deng D, Wang Q,
Peng H, Wang S and Wei Z: FOXQ1 mediates the crosstalk between
TGF-β and Wnt signaling pathways in the progression of colorectal
cancer. Cancer Biol Ther. 16:1099–1109. 2015. View Article : Google Scholar : PubMed/NCBI
|
